Caveolin-1: a novel prognostic biomarker of radioresistance in cancer.
Caveolin-1 is a membrane protein highly expressed in many tumors and plays an important role in tumor progression and metastasis. This review describes the structure of the Caveolin-1 protein and its pre-clinical and clinical significance, demonstrating that Caveolin-1 is a novel biomarker for radioresistance which has the promising potential to improve the clinical outcome of cancer patients undergoing radiation treatment.



Targeted radiation therapy has shown immense benefits for cancer treatment. However, one of the major challenges for effective clinical outcome of radiation therapy for cancer patients is the development of radioresistance during radiation treatment. As a consequence, radiation therapy becomes a less effective modality for successful clinical outcome. Furthermore, a radioresistant tumor has the ability to repair its genome, and therefore becomes more aggressive and metastasizes. The plausible mechanisms for tumor radioresistance include the rapid DNA repair, somatic mutations in tumor oncogenes, aberrant activation of kinase pathways, and changes in the tumor microenvironment including tumor hypoxia, tumor vasculature, and cancer stem cells. Caveolin-1 is significantly upregulated in certain cancer cells and aberrantly mediates downstream signaling mechanisms. Notably, numerous recent research reports have shown the role of Caveolin-1 in tumor radioresistance and poor treatment outcome. Thus, Caveolin-1 could be a novel prognostic biomarker to monitor tumor radioresistance in cancer patients undergoing radiation therapy.



Caveolin-1 has the promising potential to become a novel prognostic biomarker to monitor tumor radioresistance and radiation response specifically in the prostate, pancreas, and lung cancer.
a Division of Translational Radiation Sciences, Department of Radiation Oncology , School of Medicine, University of Maryland , Baltimore , MD , USA.
Javed
J
Mahmood
a Division of Translational Radiation Sciences, Department of Radiation Oncology , School of Medicine, University of Maryland , Baltimore , MD , USA.
Sarthak R
SR
Zaveri
a Division of Translational Radiation Sciences, Department of Radiation Oncology , School of Medicine, University of Maryland , Baltimore , MD , USA.
Stephanie C
SC
Murti
a Division of Translational Radiation Sciences, Department of Radiation Oncology , School of Medicine, University of Maryland , Baltimore , MD , USA.
Allen A
AA
Alexander
a Division of Translational Radiation Sciences, Department of Radiation Oncology , School of Medicine, University of Maryland , Baltimore , MD , USA.
Caroline Q
CQ
Connors
b Department of Pharmaceutical Sciences , School of Pharmacy, University of Maryland , Baltimore , MD , USA.
Hem D
HD
Shukla
a Division of Translational Radiation Sciences, Department of Radiation Oncology , School of Medicine, University of Maryland , Baltimore , MD , USA.
Zeljko
Z
Vujaskovic
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D051242:Caveolin 1 / Q000378:metabolism*; D019317:Evidence-Based Medicine; D015972:Gene Expression Regulation, Neoplastic / Q000528:radiation effects*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000532:radiotherapy*; D011379:Prognosis; D011836:Radiation Tolerance; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D051242:Caveolin 1
Biomarker; Caveolin; carcinoma; radiation therapy; radioresistance